(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 16.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.52%.
Bioage Labs's earnings in 2026 is -$94,464,000.On average, 12 Wall Street analysts forecast BIOA's earnings for 2026 to be -$113,787,617, with the lowest BIOA earnings forecast at -$130,888,805, and the highest BIOA earnings forecast at -$93,492,004. On average, 12 Wall Street analysts forecast BIOA's earnings for 2027 to be -$101,730,499, with the lowest BIOA earnings forecast at -$140,334,389, and the highest BIOA earnings forecast at -$13,493,691.
In 2028, BIOA is forecast to generate -$120,153,518 in earnings, with the lowest earnings forecast at -$153,649,082 and the highest earnings forecast at -$86,263,240.